Information on the EAMS scientific opinion given to nivolumab for lung cancer, including the public assessment report.
Nivolumab for lung cancer EAMS public assessment report
PDF, 78.7KB, 3 pages
This file may not be suitable for users of assistive technology.Request a different format.
This positive scientific opinion was issued to Bristol-Myers Squibb Pharmaceutical Limited on 19 June 2015 for nivolumab, in treatment of advanced lung cancer (characterised by squamous non-small cells), which has spread or cannot be removed by surgery following other cancer chemotherapies.
The scientific opinion includes:
- a public assessment report
- a treatment protocol:
- for healthcare professionals
- for patients
- on the pharmacovigilance system
Posted on the UK MHRA website on 29 June 2015
